Patients with diabetes melliutus
Conditions
Interventions
Insulin glargine group Insulin glargine-treated patients continued to receive glargine on a fasting blood glucose target of <
120mg/dL.
Insulin degldec group 1.The patients initially changed glargine to degludec. 2.After the changing, patients received degldec for 12 weekson a fasting blood glucose target of <
120 mg/dL.
Sponsors
MACHIDA MUNICIPAL HOSPITAL
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Insulin glargine-treated patients with type 1 and 2 diabetes.
Exclusion criteria
Exclusion criteria: 1. Patients with history of diabetic ketoacidosis, or diabetic coma within 6 months prior to the study entry. 2. Patients with during pregnancy or lactation. 3. severe infection, before operation, severe trauma 4. Patients who received steroid therapy 5. Patients with history of cardiac failure. 6. Patients with renal insufficiency (serum creatinine > 1.5mg/dl (male) , > 1.3mg/dl (female), e-GFR < 50ml/min). 7. Patients with severe liver dysfunction. 8. Patients who are hypersensitive to these medicines 9.Patients judged to be inappropriate by physicians in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADRR | — |
Secondary
| Measure | Time frame |
|---|---|
| SMBG HbA1c 1.5AG Body weight | — |
Countries
Japan
Contacts
Public ContactSatoshi Ito
Machida Municipal Hospital Diabetes and endocrine internal medicine
Outcome results
None listed